title: [Recent advances in patient-related outcome in gynaecological cancer].
abstract: The evaluation of quality of life has become essential in gynecological oncology. Recent guidelines have been published to improve the collection, analysis and publication of the data quality of life that will make them more reliable, reproducible and integrate them into the final treatment decision. This year at ASCO, in breast cancer, the benefit of sentinel lymph node dissection compared to the quality of life has been demonstrated. New data on cognitive function in patients treated for breast cancer show the importance of the evaluation of these disorders especially among elderly patients who are at-risk populations. Medical strategies including targeted therapies can improve survival without impairing the quality of life, also with improved gastrointestinal symptoms in case of combination chemotherapy with bevacizumab in patients with ovarian cancer in a situation early recurrence. Similarly, the addition of a pathway inhibitor M- Tor (everolimus) with hormonal therapy does not induce degradation of the quality of life in women with metastatic breast cancer.
authors.affiliation: Centre de lutte contre le cancer François Baclesse, Service de recherche clinique, 3 avenue du Général-Harris, 14000 Caen, France, Centre de lutte contre le cancer François Baclesse, Département d'oncologie médicale, 3 avenue du Général-Harris, 14000 Caen, France.
authors.forename: Pierre Emmanuel
authors.initials: PE
authors.lastname: Brachet
authors.affiliation: Centre de lutte contre le cancer François Baclesse, Service de recherche clinique, 3 avenue du Général-Harris, 14000 Caen, France, Centre de lutte contre le cancer François Baclesse, Département d'oncologie médicale, 3 avenue du Général-Harris, 14000 Caen, France, CHU, côte de Nacre, Caen, France, INSERM U1086, Université de Basse-Normandie, Caen, France.
authors.forename: Florence
authors.initials: F
authors.lastname: Joly
mesh_terms: D000367:Age Factors; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000523:psychology; D003072:Cognition Disorders / Q000139:chemically induced / Q000175:diagnosis*; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000523:psychology; D017410:Practice Guidelines as Topic; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D021701:Sentinel Lymph Node Biopsy; D019529:Sexuality; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000523:psychology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab
keywords: breast cancer; cervical cancer; ovarian cancer; patient related outcomes; quality of life